Fixing the Subscription Trap
The FTC’s Negative Option Rule do-over – and what’s at stake.
Lomedico et al. v. American Behavioral Research Institute LLC, d/b/a Relaxium
22-cv-6097, S.D.N.Y.
(July 2022)
Relaxium
Misleadingly marketing that the supplement is a “clinically proven” sleep aid when the only scientific study conducted on the product was inadequate and sponsored by Relaxium
Falsely advertising that the supplement was developed by a “sleep expert” when he has no experience or background in treating sleep disorders
The FTC’s Negative Option Rule do-over – and what’s at stake.
Be wary of questionable and deceptive claims in origin stories.
Mounting lawsuits accuse Meta of breaking privacy promises.
Breaking down the fine print of this March Madness commercial.
Advertised $19.99 price deserves an official review.